Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter
US11231429B2 · kind B2 · utility
1Cited by
1References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 8, 2018 |
| Grant date | Jan 25, 2022 |
| Priority date | — |
| Expiry date | Apr 25, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG16H50/30
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Methods, systems and circuits evaluate a subject's CVD risk using a risk parameter that includes at least one HDL and inflammatory biomarker interaction parameter. The inflammatory biomarker may optionally comprise NMR derived measurements of GlycA from at least one biosample of the subject. The risk parameter may be gender-specific.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.